Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients

Inclusion Criteria: * Male ≥ 20 years of age * Histologically or cytologically confirmed adenocarcinoma of the prostate * Presents with at least 2 bone metastases, confirmed by scintigraphic imaging within the previous 4 weeks * Patients who has failed initial hormonal therapy using either an orchiectomy or a Gonadotropin releasing hormone (GnRH) agonist in combination with an antiandrogen must first progress through antiandrogen withdrawal prior to being eligible. The minimum timeframe to document failure of anti-androgen withdrawal will be four weeks * Progressive castration resistant metastatic disease * Castrate level of testosterone (\<50 ng/dL), treatment to maintain castrate levels of testosterone must be continued Exclusion Criteria: * Has received an investigational drug in the 4 weeks before or is scheduled to receiving one during or in the 8 weeks after study drug administration. * Has received chemo-, immuno-, or radiotherapy within the last 4 weeks prior to entry in the study, or has not recovered from acute adverse events as a result of such therapy * Has received prior hemibody external radiotherapy * Has a need for immediate external radiotherapy * Has received systemic radiotherapy with radium-223, strontium-89, samarium-153, rhenium-186 or rhenium-188 for the treatment of bony metastases within the last 24 weeks prior to administration of study drug * When receiving bisphosphonates, has changed the dose within 4 weeks before administration of study drug